Profile data is unavailable for this security.
About the company
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
- Revenue in USD (TTM)1.73m
- Net income in USD1.64bn
- Incorporated2024
- Employees166.00
- LocationInhibrx Biosciences Inc11025 N. Torrey Pines Road, Suite 140LA JOLLA 92037United StatesUSA
- Phone+1 (858) 795-4220
- Fax+1 (302) 636-5454
- Websitehttps://inhibrx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scilex Holding Co | 50.83m | -171.53m | 105.77m | 113.00 | -- | -- | -- | 2.08 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
Procaps Group SA | 414.10m | 52.20m | 125.23m | 5.50k | 2.13 | 3.18 | 1.80 | 0.3024 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
Telomir Pharmaceuticals Inc | 0.00 | -22.96m | 132.36m | 1.00 | -- | 299.40 | -- | -- | -0.8145 | -0.8145 | 0.00 | 0.0149 | 0.00 | -- | -- | 0.00 | -721.99 | -- | -1,752.70 | -- | -- | -- | -- | -- | -- | -2.06 | 0.00 | -- | -- | -- | -1,430.39 | -- | -- | -- |
Puma Biotechnology Inc | 243.57m | 23.24m | 142.35m | 185.00 | 6.11 | 2.00 | 4.09 | 0.5845 | 0.475 | 0.475 | 5.03 | 1.45 | 1.15 | 17.91 | 5.83 | 1,316,589.00 | 10.95 | -12.21 | 18.85 | -20.53 | 69.29 | 78.78 | 9.54 | -11.79 | 1.40 | 3.61 | 0.5234 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
Elutia Inc | 24.78m | -60.29m | 152.07m | 54.00 | -- | -- | -- | 6.14 | -2.10 | -1.84 | 0.8695 | -1.16 | 0.4813 | 2.82 | 8.52 | 458,925.90 | -117.08 | -42.93 | -649.22 | -79.34 | 42.41 | 43.32 | -243.28 | -64.16 | 0.849 | -1.18 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
LifeVantage Corp | 196.01m | 4.13m | 164.83m | 217.00 | 41.23 | 5.93 | 21.71 | 0.8409 | 0.3192 | 0.3192 | 15.27 | 2.22 | 3.06 | 2.50 | 71.64 | 903,290.30 | 6.46 | 9.95 | 10.17 | 15.55 | 79.21 | 81.45 | 2.11 | 3.08 | 0.9923 | 559.36 | 0.00 | 26.95 | -6.20 | -2.40 | 15.63 | -16.94 | -2.18 | -- |
Scpharmaceuticals Inc | 30.28m | -80.12m | 173.10m | 135.00 | -- | 5.64 | -- | 5.72 | -1.91 | -1.91 | 0.7417 | 0.6137 | 0.262 | 0.7268 | 4.52 | 224,281.50 | -69.31 | -38.23 | -78.18 | -42.31 | 69.72 | -- | -264.60 | -1,360.16 | 6.89 | -8.42 | 0.6246 | -- | -- | -- | -48.79 | -- | -- | -- |
Mediwound Ltd | 20.14m | -19.97m | 180.78m | 100.00 | -- | 8.71 | -- | 8.98 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Inhibrx Biosciences Inc | 1.73m | 1.64bn | 202.37m | 166.00 | 0.117 | 1.13 | 0.123 | 116.71 | 119.47 | 119.47 | 0.0499 | 12.33 | 0.0058 | -- | 4.41 | 10,445.78 | 552.15 | -77.06 | 637.71 | -93.91 | -- | -- | 94,778.95 | -1,590.91 | -- | -45.76 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Biostem Technologies Inc | 210.39m | 14.32m | 219.71m | 67.00 | 21.41 | 9.65 | 15.11 | 1.04 | 0.6302 | 0.6302 | 10.58 | 1.40 | 3.82 | 8.46 | 5.01 | -- | 26.03 | -- | 135.75 | -- | 94.84 | -- | 6.81 | -- | 1.23 | 27.98 | 0.1576 | -- | -- | -- | -- | -- | -- | -- |
Lifecore Biomedical Inc | 128.45m | 5.71m | 257.05m | 524.00 | 188.96 | -- | 17.86 | 2.00 | 0.0369 | 0.0595 | 3.82 | 1.28 | 0.5217 | 2.01 | 4.96 | 245,124.00 | 2.32 | -5.91 | 2.74 | -8.33 | 34.65 | 31.01 | 4.45 | -19.16 | 0.803 | 0.125 | 0.7641 | -- | 24.20 | -25.46 | 114.53 | 34.47 | -16.72 | -- |
Precigen Inc | 3.96m | -139.56m | 257.82m | 202.00 | -- | 4.78 | -- | 65.06 | -0.5479 | -0.5479 | 0.0154 | 0.1891 | 0.0289 | -- | 5.40 | 19,618.81 | -101.81 | -31.50 | -126.84 | -38.63 | -12.44 | 44.00 | -3,521.68 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Eton Pharmaceuticals Inc | 34.68m | -5.48m | 277.74m | 30.00 | -- | 17.38 | -- | 8.01 | -0.2135 | -0.2135 | 1.34 | 0.6186 | 1.03 | 9.44 | 7.63 | 1,155,900.00 | -16.27 | -46.22 | -29.44 | -58.20 | 59.30 | 72.16 | -15.81 | -76.86 | 1.41 | -- | 0.2052 | -- | 48.90 | -- | 89.62 | -- | 26.85 | -- |
Holder | Shares | % Held |
---|---|---|
Viking Global Investors LPas of 30 Sep 2024 | 1.79m | 12.35% |
Perceptive Advisors LLCas of 30 Sep 2024 | 1.06m | 7.35% |
BlackRock Fund Advisorsas of 30 Sep 2024 | 655.51k | 4.53% |
Walleye Capital LLCas of 30 Sep 2024 | 550.00k | 3.80% |
The Vanguard Group, Inc.as of 30 Sep 2024 | 512.59k | 3.54% |
Slotnik Capital LLCas of 30 Sep 2024 | 369.35k | 2.55% |
Millennium Management LLCas of 30 Sep 2024 | 289.36k | 2.00% |
Geode Capital Management LLCas of 30 Sep 2024 | 251.22k | 1.74% |
Morgan Stanley & Co. LLCas of 30 Sep 2024 | 208.91k | 1.44% |
Caption Management LLCas of 30 Sep 2024 | 200.00k | 1.38% |